Glucagon-like peptide 1 as a regulator of food intake and body weight: Therapeutic perspectives

European Journal of Pharmacology

Volumn 440, Issue 2-3, 2002, Pages 269-279

  Meier, Juris J ^a   Gallwitz, Baptist ^a   Schmidt, Wolfgang E ^a   Nauck, Michael A ^b,c  

^a ST JOSEF HOSPITAL   (Germany)

^b Diabeteszentrum   (Germany)

^c Tel: +49 5524 81218 ^*  (Germany)

Author keywords

(GLP 1) glucagon like peptide 1; Food intake; Obesity; Satiety

Indexed keywords

GLUCAGON LIKE PEPTIDE 1;

ANOREXIA; ARTICLE; BIOSYNTHESIS; BLOOD LEVEL; BODY WEIGHT; CALORIC INTAKE; CENTRAL NERVOUS SYSTEM; CIRCULATION; CONCENTRATION RESPONSE; FEEDING; FOOD INTAKE; GLUCAGON RELEASE; HALF LIFE TIME; HUMAN; HUNGER; INGESTION; INSULIN RELEASE; L CELL; MEAL; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REDUCTION; STIMULATION; STOMACH ACID SECRETION;

ANIMALS; BODY WEIGHT; EATING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; OBESITY; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0037066595     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01434-6     Document Type: Article

References (125)

1. Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): Characterization of binding sites for GLP-1 on alpha-TSH cells
2. Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line
3. Hamster preproglucagon gene contains the sequence of glucagon and two related peptides
4. Glucagon-like peptide-1, satiety and appetite control
5. Inhibition of food intake by inhibitors of fatty acid synthase
6. A gastric inhibitory polypeptide II. The complete amino acid sequence
7. Electron immunocytochemical evidence of the K cell localisation of gastric inhibitory polypeptide (GIP) in man
8. Identification of the intestinal cell storing gastric inhibitory polypeptide
9. Glucagon-like polypeptides in canine brain
10. The incretin concept today
11. Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels
12. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
13. 2-terminus in type 2-diabetic patients and in healthy subjects
14. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
15. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
16. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats
17. Glucagon gene expression in vertebrate brain
18. Glucagon-like peptide 1 reduces postprandial glycemic excursions in IDDM
19. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
20. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man
21. Plasma insulin response to oral and intravenous glucose administration
22. Isolation and characterisation of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas
23. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line
24. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells
25. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide
26. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans
27. Glucagon-like peptide-1(7-36)amide: Characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells
28. Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells
29. Structure-activity characterization of glucagon-like peptide-1
30. Binding characteristics of N-terminal GIP/GLP-1 hybrid peptides
31. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro
32. Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary
33. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy
34. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus
35. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
36. Glucagon-like peptide-1: A potent regulator of food intake in humans
37. Sustained appetite suppression and weight loss in obese rhesus monkeys treated with a long-acting GLP-1 derivative, NN2211 (abstract)
38. Role of GLP-1 in meal-taking (abstract)
39. Gut hormones as pharmaceuticals: From enteroglucagon to GLP-1 and GLP-2
40. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
41. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut
42. Proglucagon processing in porcine and human pancreas
43. Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase
44. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1 positive pancreatic ductal cells into insulin-secreting cells
45. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
46. Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung
47. Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases
48. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
49. Glucagon-like peptide-1 [7-36]: A physiological incretin in man
50. Characterization of glucagon-like peptide-1-(7-36)amide in the hypothalamus
51. 2 in the central control of feeding behaviour
52. One-week continuous infusion of GLP-1 (7-37) improves glycaemic control in NIDDM (abstract)
53. Systemic administration of the long-acting GLP-1 analogue, NN2211, induces lasting and reversible loss of body obesity (abstract)
54. Gut-type glucagon immunoreactivity in nerves of the rat brain
55. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem
56. Repeated intracerebroventricular administration of glucagon-like pepitide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat
57. Chromatographic resolution and kinetic characterisation of glucokinase from islet of Langerhans
58. Reduced insulinotropic effects of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes
59. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
60. Vagal hepatopancreatic reflex evoked by intraportal appearance of GLP-1
61. Insulinotropic action of glucagon-like peptide 1 (7-37) in diabetic and non-diabetic subjects
62. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
63. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
64. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
65. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
66. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
67. Glucagon-like peptide 1
68. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes
69. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
70. Normalisation of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients
71. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: Evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake
72. 2: A physiological inhibitor of gastric acid secretion in man
73. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue
74. Glucagon-like peptide 1 (7-36)-amide receptors only in islets of Langerhans. Audioradiographic survey of extracerebral tissues in rats
75. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach
76. Complete sequences of glucagon-like peptide-1 from human and pig small intestine
77. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I
78. The GLP-1 analogue LY307161, potently lowers post prandial blood glucose in subjects with type 2 diabetes (abstract)
79. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach
80. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide
81. Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog
82. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidine
83. Attenuated GLP-1 secretion in obesity: Cause or consequence?
84. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships
85. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in zucker obese rats
86. Efficiacy of the long-acting GLP-1 derivate NN 2211 in diabetic ob/ob mice (abstract)
87. Characterisation of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: Lack of coupling to either stimulation or inhibition of adenyate cyclase
88. Glucagon-like-peptide (GLP)-1-(7-36)-amide: A central suppressor of food intake in rats
89. Gastric emptying and release of incretin hormones after glucose ingestion in humans
90. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men
91. Effects of glucagon-like peptide-1 (7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans
92. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans
93. Glucagon-like peptide 1 but not glucagon-like peptide 2 stimulates insulin release from isolated rat pancreatic islets
94. Model for the regulation of energy balance and adiposity by the central nervous system
95. Central nervous system control of food intake
96. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene
97. Elimination of glucagon-like peptide 1R signalling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action
98. The central neural connections of the area postrema of the rat
99. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain
100. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus
101. Biological activity of GLP-1-analogues with N-terminal modifications
102. Long-acting GLP-1 derivate NN2211 markedly attenuates diabetes development in the male zucker diabetic fatty rat (abstract)
103. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats
104. Identification and localisation of glucagon-related peptides in rat brain
105. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
106. Glucagon-like peptide 1 (7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment
107. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats
108. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1
109. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in Type 2 diabetic patients
110. Inhibitory effect of glucagon-like peptide-1 on small bowel motility
111. A role for glucagon-like peptide-1 in the central regulation of feeding
112. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
113. Characterization of high-affinity receptors for truncated glucagon-like peptide-1 in rat gastric glands
114. Glucagon-like peptide 1: A potent glycogenic hormone
115. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans
116. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose
117. Insulin secretagogue activity in vitro and in perfused pancreas of dipeptidase IV resistant GLP-1 analogues (abstract)
118. Distribution of GLP-1 and PACAP receptors in human tissues
119. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
120. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation
121. Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1
122. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo
123. Exendin-4 stimulates both b-cell replication and neogenesis, resulting in increased b-cell mass and improved glucose tolerance in diabetic rats
124. Glucose lowering and insulin-sensitizing actions of exendin-4
125. GLP-1 for six weeks reduces body weight and improves insulin sensitivity and glycemic control in patients with Type 2 diabetes